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RESUM
En els humans, el cP450arom és el producte d’un gen únic (CYP19), localitzat en el cromo-
soma 15q21.1. A la placenta, l’aromatització activa dels andrògens protegeix el fetus femella
i la mare de les accions virilitzants dels andrògens fetals. De fet, els nadons 46XX amb defici-
ència completa de l’aromatasa neixen amb una ambigüitat dels genitals externs. Els estudis en
pacients afectats per la deficiència completa del cP450arom han contribuït considerablement a
l’anàlisi de la importància de l’activitat de la cP450arom en la diferenciació sexual, en el patró de
secreció de les gonadotrofines, en la capacitat reproductora, en el metabolisme lipídic i la sensi-
bilitat a la insulina, i en el creixement i la maduració esquelètica, en ambdós sexes. La seqüència
codificant de la proteïna està continguda en nou exons (exons 2-10), que s’estenen aproxima-
dament al llarg de 35 kb de DNA. Els codons d’iniciació i terminació de la traducció són als
exons 2 i 10, respectivament. Fins ara, s’han documentat onze casos de deficiència completa de
l’aromatasa secundaris en mutacions del gen CYP19. El patró dels nivells sèrics hormonals in-
dica una baixa concentració d’estrògens i alta d’andrògens, FSH, i, ocasionalment, també d’LH,
sempre, però, depenent de l’edat i del sexe. Durant la infantesa, s’observa un dimorfisme se-
xual en el paper dels estrògens en la regulació de la secreció de les gonadotrofines. Aquests
pacients presenten un risc elevat de desenvolupar quists d’ovari, fins i tot abans de la pubertat.
Finalment, l’estudi d’aquests pacients també ha estat útil per ill. ustrar el paper dels estrògens
en el desenvolupament esquelètic, en la maduració de les epífisis i en el brot de creixement
puberal, en ambdós sexes.Paraules clau: aromatasa, ambigüitat sexual, creixement puberal, malaties genètiques.
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SUMMARY
In humans, cP450arom appears to be the product of a single gene (CYP19), located on chro-
mosome 15q21.1. In the placenta, the active aromatization of androgens protects the female
fetus and the mother from the virilizing actions of fetal androgens. Indeed, 46, XX neonates
with complete aromatase deficiency are born with ambiguous external genitalia. Studies car-
ried out on patients with complete cP450arom deficiency have also contributed considerably
to the analysis of the importance that cP450arom activity has on sexual differentiation, the pat-
tern of gonadotropin secretion, reproductive capacity, lipid metabolism and insulin sensitivity,
as well as growth and skeletal maturation in both sexes. The protein coding sequence is con-
tained within nine exons (exons 2-10), which span approximately 35 kb of DNA. The transla-
tion, initiation and termination codons are present in exons 2 and 10, respectively. Eleven well-
documented cases of complete aromatase deficiency, secondary to mutations of the CYP19 gene,
have been reported. Very low estrogens and high androgens, FSH, and sometimes LH, depend-
ing on age and sex, characterize the pattern of serum hormones. During infancy, a sexual di-
morphism has been observed in the role that estrogens play in the regulation of gonadotropins.
These patients are at risk of developing ovarian cysts, even before puberty. Finally, the study of
these patients has also been useful to illustrate the essential role of estrogens in skeletal devel-
opment, epiphysial maturation, and in the pubertal growth spurt in both sexes.Keywords: Aromatase, sexual ambiguity, puberal growing, genetic illnesses.
INTRODUCTION
Aromatase is the enzyme complex that cat-
alyzes the synthesis of estrogens from an-
drogens. Therefore, the activity arising from
this enzyme complex affects both androgen
metabolism and estrogen synthesis. The bio-
logical importance of aromatase complex ac-
tivity is related not only to its role in the
synthesis of estrogens, but also to its poten-
tial influence in the balance of the androgen-
estrogen ratio in several tissues. This enzyme
complex, which is expressed in the endo-
plasmic reticulum of cells, consists of two
components: a cytochrome P450 (cP450arom)
and coupled to it, a ubiquitous flavoprotein,
NADPH-cytochrome P450 reductase. The cat-
alytic process requires the sequential trans-
fer of three pairs of electrons, and it con-
sumes three moles of reduced NADPH to
catalyze a series of three hydroxylations in
the synthesis of one mole of estrogen. Even
though androstenedione and testosterone are
the most common and the most physio-
logically important substrates, 16OH-dehy-
droepiandrosterone sulfate (16OH-DHEAS),
arising from the fetal liver hydroxylation of
fetal adrenal DHEAS, is also an important
substrate for placental estriol synthesis dur-
ing pregnancy in both humans and high
primates. Moreover, the fact that the affin-
ity of androstenedione for cP450arom is in
the nanomolar range (at least one order of
magnitude higher than that of most other
microsomal steroid hydroxylases) represents
an important mechanism to facilitate estrogen
synthesis in peripheral, non-classical steroido-
genic tissues.
In humans cP450arom appears to be the
product of a single gene (CYP19 gene) that is
localized on chromosome 15q21.1. The protein
coding sequence is contained within nine ex-
ons (exons 2-10), which span approximately
35 kb of DNA (Means et al., 1989). The trans-
lation, initiation and termination codons are
present in exons 2 and 10, respectively. How-
ever, there are multiple first exons that are
involved in tissue-specific expression. These
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exons are not translated, and they generate
alternative splicing in such a fashion that
the coding region and, hence, the protein se-
quence, is conserved in every tissue. These
promoters are found within a 90 kb region,
upstream of the coding region (Means et al.,
1989). The most highly conserved region (the
core region), defined by a three-dimensional
model of the cP450arom, consists essentially
of a four-helix bundle: two beta sheets and
the heme-binding region. cP450arom is ex-
pressed in a number of tissues, including
the syncytiotrophoblast layer of the placen-
ta, the gonads, adipose tissue, bone, brain (in-
cluding the hypothalamus, hippocampus and
amygdala), coronary arteries and various fetal
tissues, including the liver, skin, the intes-
tine, testes and ovaries (Graham-Lorence et al.,
1995).
CYP19 gene expression is subjected to
multi-factorial regulations by a diverse group
of hormones and factors that differ markedly
in different tissues. These regulators, which
act via specific receptors that bind responsive
cis-acting elements at the 5′ flanking region,
include: gonadotropins, cyclic AMP analogs,
phorbol esters, growth factors, such as epider-
mal growth factor and transforming growth
factor beta, and steroids. Thus, a strict control
over tissue-specific expression is necessary
for an exquisite regulation of estrogen syn-
thesis, as early as during fetal development,
as well as during the post-natal life span. In
humans, several molecular CYP19 gene alter-
ations, associated with complete cP450arom
deficiency, have been described. They have
contributed considerably to the analysis of
the importance of cP450arom activity on dif-
ferent body tissues, on sexual differentiation,
the pattern of gonadotropin secretion by the
hypothalamo-pituitary axis and reproductive
capacity, lipid metabolism and insulin sensi-
tivity, and growth and skeletal maturation in
both sexes.
THE ROLE OF AROMATASE
IN THE PLACENTA
The placenta is derived from two major
cell lineages: the embryonic trophoblasts that
give rise to the epithelial parts and the extra-
embryonic mesoderm that gives rise to the
stromal cells and blood vessels of the placenta.
The precursor trophoblastic lineage differenti-
ates either into extra-villous cytotrophoblasts
(inherently invasive) that are associated with
maternal blood vessels in the outer layer of
the placenta or multi-nucleated syncytiotro-
phoblasts, located in the chorionic villae in the
innermost layer.
It has been known for many years that
there is a large production of steroids after the
second month of pregnancy. In most physio-
logical instances, including ovarian secretion,
estrogen synthesis is the consequence of the
cooperative effect of two cells, one with the
capability of synthesizing androgens and the
other, of expressing aromatase. Pregnancy is
no exception to this rule. Indeed, there is an
interaction between the fetal adrenal gland,
site of the synthesis and secretion of andro-
gen precursors, and the placenta, rich in aro-
matase and other enzymes necessary to con-
vert androgens into estrogens (Siiteri et al.,
1963). The aromatase gene is specifically ex-
pressed in syncytiotrophoblasts, and it is un-
der the regulation of a placental-specific en-
hancer.
For steroidogenesis, the feto-placental unit
synthesizes cholesterol in the fetal liver, which
is transported to the fetal adrenal as LDL cho-
lesterol. The fetal zone of the fetal adrenal is
quite enlarged, and it has the biosynthetic ma-
chinery to form DHEAS from cholesterol in
large quantities. Cholesterol is converted into
∆5-pregnenolone by the enzyme cytochrome
P450scc. A deficiency in 3β-hydroxysteroid
dehydrogenase (3β-HSD), present in the fe-
tal zone, is a pre-requisite for the synthe-
sis of this and other ∆5-steroids. An ac-
tive 17α-hydroxysteroid dehydrogenase/17,
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20 desmolase is also necessary. Finally, ∆5-
steroid sulfoconjugation is also very active in
the fetal zone of the fetal adrenal. The fetal
liver is also rich in 16α-hydroxylase, which
contributes to the synthesis of 16α-DHEAS.
After secretion,DHEAS and other sulfoconju-
gates are transported, via the umbilical artery,
to the placenta.
The placenta is an efficient extractor and
processor of ∆5-sulfoconjugates. The placenta
is rich in sulfatases, 3β-HSD and aromatase,
all necessary steps in the synthesis of es-
trogens from the DHEAS and 16α-DHEAS,
provided by the fetus. DHEA is first con-
verted into ∆4-androstenedione by 3β-HSD,
followed by the generation of the biologi-
cal active androgen testosterone through the
action of 17β-HSD. Finally, the very active
placental aromatase allows for the synthesis
of estrone, estradiol and estriol. The mater-
nal blood concentration of these three estro-
gens increases gradually during pregnancy
to reach values, at term, 50-fold higher than
those in non-pregnant women’s blood.
The active aromatization of androgens pro-
tects the fetus and the mother from the vir-
ilizing actions of androgens. In the case of
the female fetus, this is particularly impor-
tant, in order to avoid an androgenic effect,
not only on the differentiation of external gen-
italia, but also on the central nervous system,
which could program the brain during fetal
and neonatal life for non-cyclic hypothalamic
GnRH function, male sex self-identity, and
male sexual behavior.
Aside from being essential to the neutraliza-
tion of androgens, it has been postulated that
during pregnancy estrogens are important for
pregnancy maintenance and the maturation
of maternal and fetal organ systems (Pepe et
al., 1995). Estrogens could regulate the func-
tional differentiation of placental trophoblasts
and steroid biosynthetic pathways within the
feto-placental unit, as well as utero-placental
blood flow. Along with progesterone, they
inhibit uterine contractility and the immune
system to allow for fetal antigen tolerance.
Mammary gland development, fetal lung
maturation and the regulation of placental
11β-hydroxysteroid dehydrogenase for corti-
sol-cortisone metabolism are also among the
important actions attributed to estrogens dur-
ing pregnancy.
MOLECULAR ANALYSIS
IN cP450arom DEFICIENT PATIENTS
The first case in the literature was reported
by Harada et al. (1992) on a 24 year-old prim-
igravida. She showed progressive virilization
during her third trimester of pregnancy, and
her husband had consanguinity in his pedi-
gree. The newborn girl was homozygous for
a consensus 5′-splice donor sequence muta-
tion from GT-GC, which resulted in the use
of a cryptic donor site further downstream
in intron 6, and which, therefore, generated
a transcript with an insert of 87 base pairs,
resulting in the translation of an abnormal
protein molecule with 29 extra amino acids.
After transient expression in COS-7 cells, the
aromatase cDNA of the patient was found to
produce a molecule with a trace of activity
(less than 0.3%).
The next report was described by Conte et
al. (1994) on a prepubertal girl. The patient
was a compound heterozygote for two mis-
sense mutations in exon 10, in the putative
heme-binding region of the enzyme. These
missense mutations resulted in a cysteine,
instead of the highly-conserved arginine, at
amino acid 435 (R435C), and a tyrosine, in-
stead of the conserved cysteine, at amino acid
437 (C437Y). An assay on the expressed mu-
tated proteins showed that the R435C mutant
had less than 1.1 % of the enzyme activity of
the wild-type protein molecule and that the
C437Y mutant had no aromatase activity.
The following case was described by Mor-
ishima et al. (1995) on two adult siblings, male
and female, of a consanguineous pedigree.
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The molecular analysis indicated a homozy-
gous point mutation at position 375 in exon 9
(C-T) in a highly conserved region, resulting
in a cysteine instead of an arginine (R375C).
Expression of the mutant cDNA showed that
the R375C mutation had 0.2% of the aro-
matase activity of the wild-type enzyme.
Portrait et al. (1996) described a study on
a girl with a homozygous point mutation at
position 457 in exon 10 (R457X) in a highly
conserved region, and the mutant protein was
probably inactive.
Mullis et al. (1997) described the case of a
female, diagnosed at 2 weeks of post-natal
life. Molecular analysis showed a compound
heterozygote for a point mutation /deletion,
resulting in two stop codons. The point mu-
tation was G-A at the splicing site between
exon 3 and intron 3, yielding a stop codon
3 bp downstream. The other defect was a
base pair deletion (C) in the Pro (P408, CCC,
exon 9), which corresponded to the consen-
sus aromatase region of the cP450 arom en-
zyme. A frameshift mutation occurred, re-
sulting in a nonsense codon 111 bp (37 aa)
downstream in the aromatase transcript. Ca-
rani et al. (1997) described the case of an
adult man of consanguineous pedigree, and
Ludwig et al. (1995) that of a girl also of
consanguinous pedigree; both studies found
two homozygous point mutations in exon
9, at positions 365 (G-A, R365Q) and 370
(G-A, V370M), respectively, in a highly con-
served region of the cP450arom molecule.
Expression studies on COS 1 cells, showed
that the cP450arom activity of the R365Q
mutant protein was 0.4% that of the wild-
type.
The first case of an infant boy with
cP450arom deficiency (consanguineous pedi-
gree) was described by Deladoey et al. (1999).
Molecular analysis of the CYP19 gene re-
vealed homozygosity for a C-base pair
deletion in exon 5, causing a frame shift muta-
tion and a stop codon 21 codons downstream.
The resulting protein was inactive, since func-
tional regions of the protein were not present
in the molecule.
Herrmann et al. (2002) described, in an adult
male of consanguineous parents, a homozy-
gous C-A (C-A transition) substitution in in-
tron 5 at position –3 of the splicing acceptor
site, before exon 6, causing a frameshift and
a premature stop codon, 8 bp downstream
at the end of exon 5. In the patient referred
to above, the resulting peptide, if processed,
would result in a non-functional cP450arom
enzyme, since it lacked the functional, highly-
conserved region of the protein, including
the substrate-binding pocket, the electron-
accepting site, and the heme-binding site.
Finally, we recently described another
cP450arom deficiency case (Belgorosky et al.,
2003) on a neonatal girl, admitted at 7 days
of age. The sequence analysis revealed a com-
pound, heterozygous for a point mutation
from G-A at the consensus 5’-splice donor se-
quence, a GAA- AAA mutation at c DNA
position 655 in exon 5, probably resulting in a
cryptic donor site, and anA base pair deletion,
occurring in a Glu aa (Glu 412; GAA, exon 9),
which caused a frameshift mutation and gen-
erated a stop codon 98 bp (33 aa) downstream.
As in the patients above, this resulted in a pre-
maturely terminated, non-functional protein.
AROMATASE DEFICIENCY
AND SEXUAL DIFFERENTIATION
As explained above, the active aromatiza-
tion of androgens protects the fetus against
the virilizing action of fetal androgens. It has
been known for many years that the exter-
nal genitalia of the embryo and the fetus are
extremely sensitive to androgens from any
source. By a mechanism similar to that, which
happens in congenital adrenal hyperplasia
(CAH) (i.e., excessive adrenal androgens, vir-
ilizing tumors of the pregnant mother (tumor
androgens), etc.) or during the administra-
tion of androgenic compounds to the mother,
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the external genitalia of the female fetus can
be masculinized to several degrees. In most
of the described cases of female aromatase
deficiency, a marked masculinization of the
external genitalia has been reported: e.g., an
enlarged clitoris, marked or even complete
labioscrotal fusion, but non-palpable gonads.
As expected, in all of these cases, the female
internal genitalia differentiation was not af-
fected.
In these newborns, the diagnosis of 46, XX
ambiguous genitalia, secondary to congenital
adrenal hyperplasia, which is much more fre-
quent, should be discarded. A useful clinical
fact is that, in the case of aromatase defi-
ciency, though not in CAH, signs of viriliza-
tion in the mother have been reported dur-
ing pregnancy. CAH is confirmed by finding
a high serum 17α-hydroxyprogesterone con-
centration and, in the salt losing form, a low
serum sodium and high serum potassium. If
CAH is discarded, other etiologies of 46, XX
intersex should be considered, such as true
hermaphroditism, gonadal dysgenesis, viril-
izing tumors of the mother, etc. Aromatase
deficiency is confirmed when loss-of-function
mutations of the CYP19 gene are found in the
two alleles.
THE HYPOTHALAMIC PITUITARY
GONADAL AXIS
As described above, three girls and one boy
(Harada et al., 1992; Conte et al., 1994; Dela-
doey et al., 1999; Belgorosky et al., 2003) were
studied during the first month of post-natal
life. However, the serum pattern of basal go-
nadotropins during this period was reported
in only one cP450arom deficient girl (Belgo-
rosky et al., 2003). In this index case, serum
basalLH and FSH levels were extremely high.
They increased from 8 to 26 days of age, re-
sulting in high androgen serum levels. In the
other index cases, in both sexes, serum an-
drogen levels, in particular androstenedione,
were high as well. This abnormal serum go-
nadotropin pattern could reflect a central
change in the activity of the GnRH pulse
generator, and/or an effect at the pituitary
level, presumably induced by the increment
of androgens and the decrement of estrogens
during fetal and neonatal life. However, in
the former index girl at infancy, from 2 to 6
months of age, serum basalLH levels dropped
dramatically, whereas serum basal FSH lev-
els remained clearly high; on the other hand,
in the same age period, basal levels of serum
androgens remained high. Even though it has
been proposed that in females the low estro-
gen levels of infancy are active components in
the restraint of FSH and LH secretion, it can
be proposed that androgens could also play
a negative feedback role on gonadotropin se-
cretion at this age. In keeping with this con-
cept, it has been reported that androgens,
acting directly through the androgen receptor-
mediated pathway, repress GnRH gene ex-
pression in hypothalamic GnRH-secreting
neurons. At the pituitary level, a suppression
of LHβ gene transcription through a direct in-
teraction of the androgen receptor, reducing
the Sp1 site in the distal GnRH responsive pro-
moter region, has also been described. More-
over, the decrement in serum gonadotropins
and the lower values measured during the
second semester of life are in contrast with the
increase in basal serum LH and FSH, reported
in Turner’s syndrome during the first year of
life. In another girl, reported by Mullis et al.
(1997), basal serum FSH levels and the FSH
response to GnRH were elevated at 2 months
of age, though normal basal and post GnRH
serum LH levels were found. Therefore, the
persistence of high basal serum FSH levels, re-
ported so far in the two affected infant girls,
suggests that a minimal amount of estrogen is
required for the feedback mechanism of FSH
secretion in females during infancy. However,
a large inter-individual variation of serum
FSH levels has recently been described in nor-
mal infant girls.
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In contrast to the affected girls, basal serum
FSH levels and the FSH response to GnRH
were normal in the affected boys during in-
fancy, suggesting that estrogens were not
involved in the regulation of FSH secretion
in boys. Therefore, these data indicate a sex-
ual dimorphism in the regulation of FSH se-
cretion, at least during infancy. During the
first two years of life, serum FSH is relatively
higher in normal girls than in normal boys.
The levels of FSH and inhibins are impor-
tant biomarkers of gonadal function. How-
ever, since serum inhibinB levels are consider-
ably lower in infant girls than in infant boys,
it has been proposed that inhibin B is a ma-
jor contributor to the regulation of serum FSH
secretion in boys. The fact that in the affected
boys serum-free testosterone and androstene-
dione levels were very high at 2 weeks of
post-natal life and that they decreased to the
normal range during the first month of life,
reveals a role played by cP450arom in fetal
and newborn testicular function. Indeed, it
has been described that cP450arom is highly
expressed in fetal and neonatal human testes,
compared to the testes at older prepubertal
ages. Moreover, we found that during the
newborn period, there was a vigorous incre-
ment in the testicular cell populations (Beren-
sztein et al., 2002). This cell mass growth
seemed to be mainly mediated by decreased
apoptosis. We postulated that these changes,
taking place during the neonatal period, could
be important in defining the testicular func-
tion in adults. The factors that could modulate
this growth are not known. Since it has been
described that estrogens are strong inhibitors
of cell apoptosis in several tissues, we can pos-
tulate that local testicular estrogen could be
one of the candidates, among others, for mod-
ulating testicular growth during the newborn
period. Even though small adult testes have
been described in male cP450arom deficient
patients, no information is available regard-
ing the testicular growth pattern during the
newborn and infant periods, childhood, or
puberty.
During childhood, in the five studied girls
affected with aromatase deficiency, both basal
serum and GnRH-induced FSH levels were
clearly elevated, suggesting again that mini-
mal circulating levels of estrogens (or andro-
gens as substrates) are required, not only dur-
ing infancy, but also in childhood, to restrain
pituitary FSH in normal prepubertal females.
Basal serum LH levels were normal in all
of the reported cases. Serum LH response to
GnRH was elevated during childhood. How-
ever, in the only longitudinal study of serum
LH response to GnRH and serum androstene-
dione and testosterone levels during prepu-
berty (Belgorosky et al., 2003), carried out on
an affected girl, GnRH testing was performed
at three different ages, once in early prepu-
berty and twice during late prepuberty, after
5.5 years of age, when a gradual increase in
serum androgens was detected. This finding
was in agreement with previous reports, in-
dicating that the ovary was not hormonally
quiescent during prepuberty. It was interest-
ing to find that in early puberty, along with
normal serum androgen levels, peak serum
LH response to an acute GnRH test was 10
times lower than in late prepuberty. It has
been shown that during prepuberty, the sex
hormones of extra-gonadal origin (adrenal) or
those administrated exogenously, produced
not only the development of secondary sex-
ual characteristics, but also an advance in the
induction of the onset of GnRH-dependent
puberty, both in boys and in girls. There-
fore, as we previously proposed (Belgorosky
et al., 1998), it is possible to speculate that the
pubertal serum LH response to acute GnRH
stimulation, which was detected in this aro-
matase deficient girl, could have been sec-
ondary to the prolonged effect of androgens
on the central nervous system; this could in-
clude, among other effects, the maturation of
the GH/IGF-1axis, which in turn, could re-
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sult in an irreversible maturation of the GnRH
pulse generator.
Puberty was followed in two affected fe-
males: a 14.2 year-old girl (Conte et al., 1994)
and a 12.6 year-old girl (Morishima et al.,
1995). Clinical signs of virilization were found
in the two patients. In the younger girl, Tan-
ner stage 2 pubic hair, facial comedones and
acne were noted, while in the older one, Tan-
ner stage 4 pubic hair, abundant axillary hair,
an increment in clitoris size, an undeveloped
labio minora and an unstimulated vagina
were found. There was no breast development
or menarche in either case. Basal and post
GnRH test serum LH and FSH levels were
elevated. The serum androgen levels (testos-
terone and androstenedione) were clearly
high, compared to normal values for the age
and state of sexual development, whereas
the serum estradiol levels were extremely
low. Therefore, this hormonal pattern sup-
ported the concept of a main role for estrogens
in the feedback mechanism of gonadotropin
secretion within the hypothalamo-pituitary-
gonadal axis in females. Although detailed
psychosexual studies were not reported, fe-
male psychosexual orientation was observed
in the two patients.
In affected males, pubertal development
was reported to take place at the normal age.
Three young adult patients were studied. In
one of the patients (Morishima et al., 1995),
an enlarged testicular volume was observed,
and an increment in basal serum androstene-
dione, testosterone, LH and FSH was found.
However, in the other two patients, testis vol-
ume was slightly decreased in one subject
(Hermann et al., 2002) and was very small in
the other (Carani et al., 1997). Serum andro-
gens and basal gonadotropins were normal or
slightly increased (mainly FSH). However, a
markedly elevated LH and FSH response to
GnRH was found. Thus, estrogens appeared
to be one of the components for normaliz-
ing the gonadal feedback of FSH and LH in
adult men, similar to the report on women.
The fact that the serum gonadotropin was not
as high as in castrated subjects indicated that
other factors, such as testosterone and inhibin
B, were also involved in the regulation of the
hypothalamo-pituitary-testicular axis. Unfor-
tunately, no information is available on serum
inhibin B in cP450arom deficient adult male
patients. The differences reported in testes
size were striking. A spermogram was eval-
uated on the two patients with reduced tes-
ticular volume; a decrease in motility and in
the number of spermatozoa was found in both
subjects. Similar data has been reported in
the ArKO and EαrKO mouse models (Robert-
son et al., 1999; Eddy et al., 1996), indicating
that estrogens are necessary for fertility in this
species, as well as in humans. Male gender
identity and psychosexual orientation were
observed in all of the affected male patients
described so far.
OVARIAN CYST FORMATION
Large hemorrhagic cystic ovarian follicles
have been described in human aromatase de-
ficient girls, as well as in ArKO mice, not only
in childhood, but also during infancy (Britt et
al., 2000). It has been proposed that chronic
exposure to abnormally high LH levels could
stimulate ovarian cyst development. How-
ever, female mice, homozygous for a targeted
disruption of the FSH beta subunit gene,
exhibited an approximate 5-fold increase in
serum LH, but did not develop enlarged cys-
tic follicles in the ovary, suggesting that FSH
played a role in this process, as well. Weil et
al. (1999) showed that testosterone increased
follicular FSH receptors, and it has been sug-
gested that androgens could promote follic-
ular growth by amplifying the FSH effect. It
is possible that this could partially explain
the enhanced responsiveness to gonadotropin
stimulation noted in women with polycys-
tic ovary syndrome. According to these data,
we can speculate that, in aromatase deficient
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prepubertal patients, an amplification of FSH
signaling could occur in the presence of high
intra-ovarian androgen production and that
this mechanism could be involved in the de-
velopment of ovarian follicular cysts.
In one pubertal girl, a large bilateral cyst
mass was observed in a pelvic ultrasonog-
raphy. After abdominal exploration, several
multi-lobulated cystic masses were found in
the two ovaries, confirming that large follic-
ular cysts can be observed from infancy to
adulthood in cP450arom deficient patients. It
is remarkable that the histopathology of the
cystic masses of this patient was compatible
with the diagnosis of polycystic ovary syn-
drome.
GROWTH, SKELETAL MATURATION
AND BONE MASS
Longitudinal bone growth results from the
expansion of the growth plate cartilage by
regional chondrocyte proliferation, hypertro-
phy, and the secretion of the extra-cellular
matrix. The extra-cellular matrix produced by
chondrocytes calcifies and is replaced by bone
during the process of endochondral ossifica-
tion. The epiphyseal fusion of long bones is
the result of a progressive decrease in cartilage
expansion. Thus, when the vascular invasion
exceeds cartilage expansion, there is a pro-
gressive thinning of the growth plate. This
mechanism is mediated in large part by the ac-
tion of estrogen during puberty. In this regard,
aromatase transcripts and the cP450arom pro-
tein have been detected in the human growth
plate. In addition, it is also known that estro-
gen receptors are expressed in chondrocytes.
These data support the concept that local es-
trogens play a prominent role in the control of
long bone growth and growth plate matura-
tion (Turner et al., 1994).
In both sexes, bone mass clearly increases
during puberty through a combination of in-
creased bone length, bone diameter, cortical
bone width, and cancellous bone mass. It has
been proposed that these effects are mod-
ulated by sex steroids and other hormonal
changes, which take place during puberty.
Cortical bone mass could continue to increase
after final height is achieved (Turner et al.,
1994).
In one estrogen receptor α affected adult
male and in three cP450arom deficient adult
males, tall stature, unfused epiphyses, os-
teopenia, eunuchoid skeletal proportions, and
genu valgum were observed. Pubertal height
velocity was apparently constant, and tall
stature was the consequence of a lack of epi-
physeal fusion. These cases illustrated the
essential role of estrogens in skeletal devel-
opment and in the growth spurt in males.
Furthermore, in 46, XY phenotypic females
with complete androgen insensitivity, the age
of peak height velocity, the pattern of skele-
tal maturation, and the timing of epiphyseal
fusion were comparable to that of normal fe-
males. On the other hand, while aromatase
inhibitors decrease rapid growth and skele-
tal maturation, anti-androgens do not affect
skeletal maturation, strongly supporting the
essential role of estrogens on the pubertal
growth spurt, skeletal maturation, and body
proportions. During childhood, even though
normal growth was observed in the three
affected girls, a delayed bone age was also
found, indicating the critical role of estro-
gen on skeletal maturation during prepuber-
tal years. However, information on the role of
estrogen on bone mineral acquisition is scarce.
In the Mullis et al. case (1997), low bone min-
eral density (BMD) was found, whereas in a
case recently reported by us, on a 7-year-old
girl, BMD was normal. Further information is
required to clarify this important issue during
prepuberty in children of both sexes.
ESTROGEN TREATMENT
In pubertal females with cP450arom defi-
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ciency (Conte et al., 1994; Morishima et al.,
1995), daily estrogen replacement therapy, as-
sociated with a progesterone compound, not
only resulted in breast development, menar-
che, growth spurt and fused epiphyses, but it
also resulted in decreases in the plasma con-
centrations of gonadotropins and androgens
and in the regression of ovarian cysts. Thus,
treatment confirmed the critical role of estro-
gens on the hypothalamo-pituitary-ovarian
axis and on bone skeletal maturation. Even
though there is no information regarding the
bone mineral mass of affected females on es-
trogen replacement therapy, it is logical to
assume that estrogen treatment could be im-
portant to improve bone mineral accretion.
The indication for estrogen treatment dur-
ing the infancy and childhood of affected
female patients is less clear. As mentioned
above, estrogen replacement therapy at pu-
berty arrests the development of ovarian cysts
and could also contribute to an increased
BMD. Mullis et al. (1997), reported that low
doses of estradiol (0.4 mg/day ), given to a
3 year-old affected girl for 50 days, resulted
in the normalization of serum gonadotropins,
the regression of her enlarged ovaries and an
improvement in BMD. However, plasma FSH
returned to pre-treatment levels, and ovarian
size increased shortly after the cessation of es-
trogens. Although the ovary is not quiescent
during the prepubertal period and a mini-
puberty has recently been described during
the first three months of age in normal girls,
there has not been much experience with re-
gards to the side effects of a chronic, low dose
administration of estradiol during early pre-
puberty. Therefore, in order to prevent the risk
of torsion of the enlarged ovaries and ovar-
ian cysts during infancy and early childhood,
long-term treatment with a GnRH analogue
could be considered as a therapeutic option.
However, the consequences of a lack of estro-
gens during infancy and early childhood on
BMD are not clearly established.
In affected adult males, the administra-
tion of low doses of estrogens inhibited
gonadotropin secretion, as well as serum
testosterone levels, supporting the idea that
estrogens play a role in the regulation of the
hypothalamo-pituitary-testicular axis. How-
ever, sperm quality and count remained ab-
normal. This lack of response could have
been, in part, secondary to a low intra-
testicular concentration of testosterone, in
turn, secondary to the inhibition of serum LH.
On the other hand, lower doses of estrogens
(transdermal estradiol 12.5 mg, twice weekly)
were indicated for 6 months and normalized
serum testosterone, as well as the serum LH
and FSH in one case (Hermann et al., 2002).
However, sperm studies were not performed
in that case. Even though the role of estrogens
on testicular development and function is not
clearly understood, an irreversible alteration
of testicular function cannot be ruled out, due
to a lack of intra-testicular estrogens at a crit-
ical period of testicular development, such as
during fetal or neonatal life.
INSULIN SENSITIVITY
AND LIPID METABOLISM
Insulin resistance (Morishima et al., 1995;
Hermann et al., 2002) and lipid profile (Carani
et al., 1997), as well as some clinical features,
similar to the metabolic syndrome, have been
described in adult male cP450arom deficient
patients. However, studies on insulin sensitiv-
ity and lipid profiles have not been performed
on adult affected females or on children of ei-
ther sex.
To date, a causal relationship between es-
trogen deficiency and carbohydrate metabo-
lism has yet to be demonstrated. Although
the abnormal lipid pattern could be related
in part to a direct effect of androgens, it has
been reported that this abnormal lipid pattern
could be improved through estrogen treat-
ment (Hermann et al., 2002).
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CONCLUSIONS
Patients with aromatase deficiency repre-
sent another “experiment of nature” that has
proven to be a fertile source of knowledge for
estrogen physiology and pathology. In partic-
ular, studies on these patients have demon-
strated the role of estrogens on bone matura-
tion, gonadotropin modulation in both sexes,
ovarian cyst formation, and testicular func-
tion, and these data have been reinforced by
the generation of aromatase and estrogen re-
ceptor knock-out mice.
From the point of view of the clinical di-
agnosis, it is important to consider this de-
ficiency in the differential diagnosis of 46,
XX patients with ambiguous genitalia and in
the association of clinical signs of virilization
and a lack of breast development at puberty.
Moreover, the finding of delayed bone age,
associated with high serum androgen levels,
is highly suggestive of some degree of aro-
matase deficiency during childhood and the
early pubertal years. This diagnosis should
also be considered in men with excessive post-
pubertal growth and infertility.
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